Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- XRTX
- Price
- 0.55
- Stock movement down
- -0.02 (-4.02%)
- Company name
- XORTX Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.86M
- Ent value
- 3.36M
- Price/Sales
- -
- Price/Book
- 1.40
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 9.37%
- 1 year return (CAGR)
- -43.71%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XRTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.40 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 6.96M |
| EPS (TTM) | -0.40 |
| FCF per share (TTM) | -0.61 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -108.46K |
| Operating income (TTM) | -3.22M |
| Net income (TTM) | -1.95M |
| EPS (TTM) | -0.40 |
| EPS (1y forward) | -0.48 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.66M |
| Net receivables | 30.78K |
| Total current assets | 1.74M |
| Goodwill | 0.00 |
| Intangible assets | 270.31K |
| Property, plant and equipment | 323.00K |
| Total assets | 3.92M |
| Accounts payable | 942.45K |
| Short/Current long term debt | 82.23K |
| Total current liabilities | 1.17M |
| Total liabilities | 1.17M |
| Shareholder's equity | 2.75M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.92M |
| Capital expenditures (TTM) | 30.70K |
| Free cash flow (TTM) | -2.95M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -70.84% |
| Return on Assets | -49.77% |
| Return on Invested Capital | -68.78% |
| Cash Return on Invested Capital | -104.26% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.58 |
| Daily high | 0.58 |
| Daily low | 0.55 |
| Daily Volume | 16K |
| All-time high | 60.39 |
| 1y analyst estimate | 13.98 |
| Beta | -0.12 |
| EPS (TTM) | -0.40 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| XRTX | S&P500 | |
| Current price drop from All-time high | -99.08% | -0.89% |
| Highest price drop | -99.13% | -19.00% |
| Date of highest drop | 20 Nov 2025 | 8 Apr 2025 |
| Avg drop from high | -98.45% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.86M
Marketcap category
Small-cap
Description
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page